RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and raises the price target from $64 to $67.
RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Raises Price Target to $67
RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and raises the price target from $64 to $67.
Related Posts
Fisker Reports Lower-Than-Expected Q2 Production Due To Supply Shortages
Fisker Inc (NYSE: FSR) disclosed Q2 2023 vehicle production volumes
SVB Leerink Maintains Market Perform on Phreesia, Raises Price Target to $31
SVB Leerink analyst Stephanie Davis maintains Phreesia (NYSE:PHR) with a Market Perform and raises the price target from $27 to $31.
Vital Farms Q4 EPS $0.04, Inline, Sales $110.10M Beat $100.29M Estimate
Vital Farms (NASDAQ:VITL) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 144.44 percent increase over losses of $(0.09) per share from the same period last year. The